Clinical trial
Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma
NCT00027508 · PharmaMar, Industry · Terminated
Key facts
| NCT number | NCT00027508 |
|---|---|
| Title | Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma |
| Official title | Phase II Study Of ET-743 In Patients With Unresectable Malignant Pleural Mesothelioma |
| Lead sponsor | PharmaMar, Industry |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Malignant Mesothelioma |
| Intervention type | Drug |
| Interventions | trabectedin |
| Start date | Jul 1, 2001 |
| Primary completion | Feb 1, 2002 |
| Completion | Feb 1, 2002 |
| First posted | Jan 15, 2004 |
| Last update posted | Feb 24, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: